Astellas Pharma, Inc. relies heavily on Xtandi (enzalutamide), the prostate cancer drug it commercializes in the US with Pfizer Inc. and the company's top revenue generator. While Xtandi still has growth potential ahead of its US loss of exclusivity, expected in 2027, Astellas is looking to bring a new generation of growth drivers to market in the US, starting with fezolinetant in women's health later this year.
Astellas Plots US Portfolio Expansion
US president Mark Reisenauer talked to Scrip about the company's next growth drivers, including fezolinetant for vasomotor symptoms and zolbetuximab for gastric cancer.
More from Strategy
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.
More from Business
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.